eribulin mesylate
Orphan Drug Cold Chain RequiredFDA Approved
Description
Eribulin mesylate is a microtubule dynamics inhibitor approved for metastatic breast cancer and unresectable or metastatic liposarcoma. It is a synthetic analog of halichondrin B, derived from a marine sponge, that inhibits microtubule growth without affecting depolymerization. Clinical trials have demonstrated improved overall survival in patients with advanced liposarcoma who received prior anthracycline-based chemotherapy.
Indications & Therapeutic Use
metastatic breast cancer, unresectable or metastatic liposarcoma, metastatic leiomyosarcoma
Linked Diseases:
liposarcoma
D008080
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
eribulin mesylate
| Generic Name | eribulin mesylate |
| Brands | 1 brand available |
| Active Ingredient | eribulin mesylate |
| Drug Class | metastatic breast cancer |
| Manufacturer | Eisai |
| Dosage Forms | IV injection 0.5mg/mL (2mg/4mL vials) |
| Medical Code | L01XX41 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01327885 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes